Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. èììóíèòåò
    îò Amon â ðàçäåëå Àëëåðãèÿ, èììóíîëîãèÿ
    Îòâåòîâ: 0
    : 16.03.2006, 11:02
  2. èììóíèòåò
    îò kniaginia â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 10
    : 01.06.2005, 20:05
  3. Èììóíèòåò
    îò Ñàìà ñåáå õîçÿéêà â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 17
    : 25.05.2005, 14:31
  4. èììóíèòåò
    îò shcnik â ðàçäåëå Ýíäîêðèíîëîã
    Îòâåòîâ: 4
    : 01.09.2004, 19:30
  5. Èììóíèòåò
    îò Oleg â ðàçäåëå Òåðàïåâò
    Îòâåòîâ: 1
    : 08.08.2003, 17:53
  1. kryl
    #16
    ×èòàòåëü Íåäóã.Ðó
    Âîïðîñ åùå âîçíèê, âûëå÷èë ëè õîòü êîãî-íèáóäü ãåðïåòè÷åñêèé öåíòð ñ èõ èììóíîêîððåêöèåé? Òàê ÷òîá áûëî ïî 6-8 ðåöèäèâîâ â ãîä, à ñòàëî 0 çà ïîñëåäíèå íåñêîëüêî ëåò? Åñëè äà , òî ñêîëüêî % ñ÷àñòëèâ÷èêîâ?

  2. succuba
    #17
    ×èòàòåëü Íåäóã.Ðó
    1. Äîêàçàííîé ýôôåêòèâíîñòüþ ïðè ÷àñòûõ ðåöèäèâàõ ãåíèòàëüíîãî ãåðïåñà ÿâëÿåòñÿ ñóïðåññèâíàÿ òåðàïèÿ. Íàçíà÷àåòñÿ ïðè êîëè÷åñòâå ðåöèäèâîâ â ãîä > 5.

     Ãåðïåòè÷åñêîì öåíòðå ïðèìåíÿþòñÿ ðàçëè÷íûå ìåòîäû ëå÷åíèÿ, â ò.÷. ïðîòèâîâèðóñíûå ïðåïàðàòû è äàæå ãîìåîïàòè÷åñêîå ëå÷åíèå.

  3. Lyuba
    #18
    ×èòàòåëü Íåäóã.Ðó
    è äàæå ãîìåîïàòè÷åñêîå ëå÷åíèå.Ñ êàêîé öåëüþ?

  4. êèðèëë 85
    #19
    ×èòàòåëü Íåäóã.Ðó
    Ñ öåëüþ ñîêðàùåíèÿ êîëè÷åñòâà ðåöèäèâîâ

  5. Maskarad
    #20
    ×èòàòåëü Íåäóã.Ðó
    Âû øóòèòå?

  6. Ïàâåë Ê.
    #21
    ×èòàòåëü Íåäóã.Ðó
    Ñ öåëüþ ñîêðàùåíèÿ êîëè÷åñòâà ðåöèäèâîâ



    È ÷òî ñèëüíî ïîìîãëî?

  7. Íàôàíÿ
    #22
    ×èòàòåëü Íåäóã.Ðó
    Îòäåëüíûì ïàöèåíòàì ãîìåîïàòèÿ îòëè÷íî ïîìîãàåò.

    Åñëè Âû â Àìåðèêà æèâ¸òå, çíà÷èò ÷èòàåòå ðàçíûå íàó÷íûå æóðíàëû. Ïî äàííûì ó÷¸íûõ ýôôåêòèâíîñòü ïëàöåáî äîõîäèò äî 30%.

  8. sergyk911
    #23
    ×èòàòåëü Íåäóã.Ðó
    ß ïðîñòóæàþñü ïðàêòè÷åñêè êàæäûé ìåñÿö

  9. Shadow
    #24
    ×èòàòåëü Íåäóã.Ðó
    Ãåðïåòè÷åñêèé öåíòð ìåíÿ ëè÷íî ãîìåîïàòèåé íå ëå÷èë. Ñìûñë òàì òàêîé - ñïåðâà àíàëèçû íà âñå èíôåêöèè, ïîòîì èììóíîãðàììà. Äàëåå ïî èììóíîãðàììå íàçíà÷àþò èììóíîìîäóëÿòîð. Àöèêëîâèð æå ðåêîìåíäóþò ïèòü òîëüêî òîãäà, êîãäà ïóçûðüêè ïîÿâëÿþòñÿ(òàê êàê ÿ ìîãó ñïóòàòü ñèìïòîìû è âûïèòü àöèêëîâèð íå ïî äåëó). Ìîå ìíåíèå æå, ÷òî ÿ áåçîøèáî÷íî çíàþ ÷òî áóäåò ðåöèäèâ(íàäåæäû íà òî ÷òî ìåíÿ ãëþ÷èò, íèêîãäà íå îïðàâäûâàþòñÿ, íå ñìîòðÿ íè íà êàêèå ïëàöåáî-âíóøåíèÿ). Íè÷åãî òîëêîì íå ðàçúÿñíÿþò, ñòàâÿò ïå÷àòü â êàðòå è ãîâîðÿò, ÷òî ïèòü ñïèðòíîå+áåðåìåíåòü íåëüçÿ, ÿ äîëæíà ðàñïèñàòüñÿ íà ïå÷àòè, ÷òî ïèòü è áåðåìåíåòü íå áóäó. Ñëåäóþùèé ïðèåì ÷åðåç ìåñÿö-äâà. Ñíîâà èììóíîãðàììû, è íîâûå èììóíîìîäóëÿòîðû. Ñíîâà ðîñïèñü. Ïîòîì îïðåäåëåíèå òèðîâ ê ãåðïåñó. Òèòðû íèçêèå – íàçíà÷åí èììóíîãëîáóëèí. Äîïîëíèòåëüíî ïðîëå÷èâàþòñÿ ñîïóòñòâóþùèå èíôåêöèè. Ãäå-òî ÷åðåç ãîä ÿ çàìåòèëà, ÷òî ðàñïèñûâàëàñü íà ïå÷àòè íå çà òî ÷òî ÿ ïèòü è áåðåìåíåòü íå áóäó, à çà òî ÷òî ÿ îçíàêîìëåíà ñ ïëàíîì ëå÷åíèÿ. Íå ïîäóìàéòå ÷òî ÿ ÷èòàòü íå óìåþ, ïðîñòî ó ìîåãî ëå÷àùåãî âðà÷à, ïå÷àòü íå ïðîïå÷àòûâàëàñü. Ñ ïëàíîì ëå÷åíèÿ ìåíÿ íèêòî íèêîãäà íå çíàêîìèë. À ïîòîì îíè ñãîðåëè âìåñòå ñ ïëàíàìè ëå÷åíèÿ, çàïèñàííûìè äîêòîðîì â êàðòå. Âîò òàêèå äåëà, ðåöèäèâû êàê áûëè , òàê è îñòàëèñü, õîðîøî ÷òî áîëüøå íå ñòàëî. Îáùàÿñü ïî íåòó, è òàêîå ïðèõîäèëîñü ÷èòàòü(ðåöèäèâû ñòàëè ïîñòîÿííûìè). Äåíåã è âðåìåíè íà ýòî ëå÷åíèå ïîòðà÷åíî íåìåðåííî. Íî ÿ âîò òîëüêî ñåé÷àñ çàäóìàëàñü, ÷òî íèêòî è íèêîãäà íå íàïèñàë íà ãåðïåñ.ðó – «Ìåíÿ âûëå÷èëè â ãåðïåòè÷åñêîì öåíòðå».

  10. kamin-kvp
    #25
    ×èòàòåëü Íåäóã.Ðó
    Ñíîâà èììóíîãðàììû, è íîâûå èììóíîìîäóëÿòîðû



    Ðåêîìåíäàöèè ÂÎÇ (2003)



    TREATMENT OPTIONS FOR GENITAL HERPES



    Recommended regimen for fi rst clinical episode



    acyclovir, 200 mg orally, 5 times daily for 7 days

    OR

    acyclovir, 400 mg orally, 3 times daily for 7 days

    OR

    valaciclovir, 1 g orally, twice daily for 7 days

    OR

    famciclovir, 250 mg orally, 3 times daily for 7 days



    Recommended regimen for recurrent infection



    acyclovir, 200 mg orally, 5 times daily for 5 days

    OR

    acyclovir, 400 mg orally, 3 times daily for 5 days

    OR

    acyclovir, 800 mg orally, twice daily for 5 days

    OR

    valaciclovir, 500 mg orally, twice daily for 5 days

    OR

    valaciclovir, 1000 mg orally, once daily for 5 days

    OR

    famciclovir, 125 mg orally, twice daily for 5 days



    Recommended regimen for suppressive therapy



    acyclovir, 400 mg orally, twice daily, continuously

    OR

    valaciclovir, 500 mg orally, once daily

    OR

    valaciclovir, 1000 mg orally, once daily

    OR

    famciclovir, 250 mg orally, twice daily



    Note

    Some experts recommend discontinuing acyclovir after one year of continuous use so that the recurrence rate can be reassessed. The lowest continuous dose that will suppress recurrences in an individual can only be determined empirically.



    Recommended regimen for severe disease



    acyclovir, 5–10 mg/kg IV, every 8 hours for 5–7 days or until clinical resolution is attained



    Recommended regimen in severe herpes simplex lesions with coinfection with HIV



    acyclovir, 400 mg orally, 3–5 times daily until clinical resolution is attained



    Recommended regimen for neonates



    acyclovir, 10 mg/kg intravenously, 3 times a day for 10–21 days



    È ÍÈÊÀÊÈÕ ÈÌÌÓÍÎÌÎÄÓËßÒÎÐÎÂ



    Ñïåöèàëüíî äëÿ jedi ââñ



    http://www.who.int/reproductive-health/publications/rhr_01_10_mngt_stis/index.html

  11. metanika
    #26
    ×èòàòåëü Íåäóã.Ðó
    Ïîõîæå, â íàøåé áîëüíèöå ïîðà îòêðûòü ïàëàòó ëîðäîâ.

  12. Timur
    #27
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé Àíòîí Âëàäèìèðîâè÷!

    Îòñòóïëåíèå êàñàëîñü íå ãèðóäèíà, à «êðîëèêîâ», òî÷íåå ïèÿâîê, êîòîðûõ ÿ áîþñü. À ýòî, êàê óæå ïèñàë âûøå, íå îäíî è òîæå. Òåõ ñàìûõ, êîòîðûõ ñíà÷àëà áîëåå äâóõ òûñÿ÷ ëåò â ìåäèöèíå èñïîëüçîâàëè. Çàòåì, ïîñëå òîãî, êàê ñîçíàíèå ìíîãèõ âðà÷åé ïîëíîñòüþ ïåðåøëî ïîä äèêòàò èäåîëîãèè EBM, íàä íèìè ñòàëè, êòî èðîíèçèðîâàòü, êòî ãíåâíî ïîíîñèòü. À ïîòîì îïÿòü ïðèçíàëè. È ïðîèçâîäñòâî, ïîòðåáíîñòü â ýòèõ ñàìûõ ïèÿâêàõ, ñóäÿ ïî ñîîáùåíèÿì ôðàíöóçîâ, íåóêëîííî ðàñòåò. Íî ýòî, Âû ïðàâû, äåéñòâèòåëüíî, òîëüêî ÷àñòíûé ïðèìåð.



    À «ãåíåðàëüíàÿ ëèíèÿ» â íàøåé ñ Âàìè áåñåäå â ýòîé äèñêóññèè, ÷òî ÿ ïðåäëîæèë Âàì ðàññïðîñèòü ñ ïðèñòðàñòèåì âðà÷à ñ èìåíåì, êîòîðûé ìíîãî ëåò çíàêîì, âèäåë ðåçóëüòàòû òåðàïèè íå íà îäíîé ñîòíå áîëüíûõ. Èëè Âû, äåéñòâèòåëüíî, âñåðüåç áóäåòå ñóäèòü î íåé ïî ñîîáùåíèÿì ñ óæàñíûìè ñòðàøèëêàìè òèïà çàðàæåíèé ãåïàòèòîì è ÂÈ× ïðè àóòîãåìîòåðàïèè, ïîæàðàìè è ò.ï.? Ðàññóæäåíèÿ, êðèòèêà Àìåðèêè îò ëþäåé, êîòîðûå íè ðàçó â íåé íå áûëè, âûçûâàåò íà ôîðóìå ãíåâíóþ îòïîâåäü, à êðèòèêà òåðàïèè îò ó÷àñòíèêîâ, êîòîðûå ñàìè íèêîãäà ñ íåé íå ñòàëêèâàëèñü, íå âèäåëè è òîëêîì íå ïðåäñòàâëÿþò – àïëîäèñìåíòû.

  13. Åâãåíèé Ì.
    #28
    ×èòàòåëü Íåäóã.Ðó
    ß õîòåëà áû çàäàòü åùå îäèí âîïðîñ.

    Â àïòåêàõ ïðîäîþò ëåêàðñòâà îñíîâàííûå íà ýõèíîöåå, ïîäñêàæèòå ïîæàëóéñòà ïîìîãàþò ëè äàííûå ëåêàðñòâà èëè ýòî ñîìîâíóøåíèå?

    Ñòîèò ëè èõ ïîêóïàòü èëè ëó÷øå êóïèòü âèòàìèíû èëè åùå ÷åãî äðóãîå?Íè âèòàìèíû, íè ýõèíàöåÿ íå ïîêàçàëè äîñòîâåðíîé ýôôåêòèâíîñòè äëÿ ïðåäóïðåæäåíèÿ ïðîñòóä.

    Ïîëíîöåííîå ïèòàíèå, çàêàëèâàíèå, ÷àñòîå ìûòüå ðóê âî âðåìÿ ýïèäåìèé ÎÐÂÈ.

  14. nika
    #29
    ×èòàòåëü Íåäóã.Ðó
    Êñòàòè, ßíî÷êà. âû ãîâîðèòå, ÷òî ïðîñòóæàåòåñü êàæäûé ìåñÿö. Ýòî äåéñòâèòåëüíî ÎÐÂÈ, à íå àëëåðãè÷åñêèé ðèíèò, íàïðèìåð?



    P.S. Íå ïîíèìàþ, ÷òî äåëàåò ãåíåðàëüíûé äèðåêòîð èçâåñòíîé øàðàøêèíîé êîíòîðû Çàéöåâ â êîíñóëüòàòèâíîì ôîðóìå?

  15. werd
    #30
    ×èòàòåëü Íåäóã.Ðó
    Âîçìîæíî ýòî ÷òî-òî àëëåðãè÷åñêîå, ò.ê. ÿ çàìåòèëà, ïðè âîçíèêíîâåíèè ñêâîçíÿêà ÿ íà÷èíàþ ÷èõàòü, è âèäèìî åñëè ñêâîçíÿê ÿ ñðàçó íå çàìå÷ó íà÷èíàåò "ëèòü" èç íîñà è ò.ä. ïî âîçðàñòàþùåé, çàëîæåíîñòü íîñà, êàøåëü, ïåðøåíèå, áîëü â ãîðëå è ïðîäîëæàþòñÿ âñå ýòè ñèìïòîìû ãäå-òî 2-3 íåäåëè, ñ òåìïåðàòóðîé ëèáî áåç.

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •